Shepard HM - Search Results

1

NB2001, a novel antibacterial agent with broad-spectrum activity and enhanced potency against beta-lactamase-producing strains.

Li Q, Lee JY, Castillo R, Hixon MS, Pujol C, Doppalapudi VR, Shepard HM, Wahl GM, Lobl TJ, Chan MF. Li Q, et al. Among authors: shepard hm. Antimicrob Agents Chemother. 2002 May;46(5):1262-8. doi: 10.1128/AAC.46.5.1262-1268.2002. Antimicrob Agents Chemother. 2002. PMID: 11959554 Free PMC article.

2

A novel approach to thymidylate synthase as a target for cancer chemotherapy.

Li Q, Boyer C, Lee JY, Shepard HM. Li Q, et al. Among authors: shepard hm. Mol Pharmacol. 2001 Mar;59(3):446-52. doi: 10.1124/mol.59.3.446. Mol Pharmacol. 2001. PMID: 11179438

3

Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 induction.

Neuteboom ST, Karjian PL, Boyer CR, Beryt M, Pegram M, Wahl GM, Shepard HM. Neuteboom ST, et al. Among authors: shepard hm. Mol Cancer Ther. 2002 Apr;1(6):377-84. Mol Cancer Ther. 2002. PMID: 12477050

4

p53-mediated accumulation of hypophosphorylated pRb after the G1 restriction point fails to halt cell cycle progression.

Linke SP, Harris MP, Neugebauer SE, Clarkin KC, Shepard HM, Maneval DC, Wahl GM. Linke SP, et al. Among authors: shepard hm. Oncogene. 1997 Jul 17;15(3):337-45. doi: 10.1038/sj.onc.1201200. Oncogene. 1997. PMID: 9233768

5

Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase.

Lackey DB, Groziak MP, Sergeeva M, Beryt M, Boyer C, Stroud RM, Sayre P, Park JW, Johnston P, Slamon D, Shepard HM, Pegram M. Lackey DB, et al. Among authors: shepard hm. Biochem Pharmacol. 2001 Jan 15;61(2):179-89. doi: 10.1016/s0006-2952(00)00542-6. Biochem Pharmacol. 2001. PMID: 11163332

6

Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy.

Singha NC, Nekoroski T, Zhao C, Symons R, Jiang P, Frost GI, Huang Z, Shepard HM. Singha NC, et al. Among authors: shepard hm. Mol Cancer Ther. 2015 Feb;14(2):523-32. doi: 10.1158/1535-7163.MCT-14-0580. Epub 2014 Dec 15. Mol Cancer Ther. 2015. PMID: 25512619

7

Inhibition of tumor cell proliferation in vitro and in vivo by exogenous p110RB, the retinoblastoma tumor suppressor protein.

Antelman D, Machemer T, Huyghe BG, Shepard HM, Maneval D, Johnson DE. Antelman D, et al. Among authors: shepard hm. Oncogene. 1995 Feb 16;10(4):697-704. Oncogene. 1995. PMID: 7862447

8

Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein.

Harris MP, Sutjipto S, Wills KN, Hancock W, Cornell D, Johnson DE, Gregory RJ, Shepard HM, Maneval DC. Harris MP, et al. Among authors: shepard hm. Cancer Gene Ther. 1996 Mar-Apr;3(2):121-30. Cancer Gene Ther. 1996. PMID: 8729911

9

Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo.

Köck H, Harris MP, Anderson SC, Machemer T, Hancock W, Sutjipto S, Wills KN, Gregory RJ, Shepard HM, Westphal M, Maneval DC. Köck H, et al. Among authors: shepard hm. Int J Cancer. 1996 Sep 17;67(6):808-15. doi: 10.1002/(SICI)1097-0215(19960917)67:6<808::AID-IJC9>3.0.CO;2-V. Int J Cancer. 1996. PMID: 8824552

10

p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus.

Anderson SC, Johnson DE, Harris MP, Engler H, Hancock W, Huang WM, Wills KN, Gregory RJ, Sutjipto S, Wen SF, Lofgren S, Shepard HM, Maneval DC. Anderson SC, et al. Among authors: shepard hm. Clin Cancer Res. 1998 Jul;4(7):1649-59. Clin Cancer Res. 1998. PMID: 9676839

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

95 results

Search Page

Filters